Gene Editing for Dyslipidemia Demonstrates Long-Term Efficacy and Safety

New clinical trial data, presented at the European Society of Cardiology Congress 2026 and published in the New England Journal of Medicine, indicates that CRISPR-Cas9 gene editing targeting the ANGPTL3 gene for refractory dyslipidemia is safe and effective for up to one year. This represents the longest follow-up for such a gene-editing approach to lipid disorders, potentially paving the way for a one-time treatment strategy. The findings are crucial for advancing gene-editing therapies.